[go: up one dir, main page]

TN2011000258A1 - Pharmaceutical composition of a potent hcv inhibitor for oral administration - Google Patents

Pharmaceutical composition of a potent hcv inhibitor for oral administration

Info

Publication number
TN2011000258A1
TN2011000258A1 TN2011000258A TN2011000258A TN2011000258A1 TN 2011000258 A1 TN2011000258 A1 TN 2011000258A1 TN 2011000258 A TN2011000258 A TN 2011000258A TN 2011000258 A TN2011000258 A TN 2011000258A TN 2011000258 A1 TN2011000258 A1 TN 2011000258A1
Authority
TN
Tunisia
Prior art keywords
pharmaceutical composition
oral administration
hcv inhibitor
potent hcv
potent
Prior art date
Application number
TN2011000258A
Other languages
English (en)
Inventor
Feng-Jing Chen
Juan Francisco Gel
Maria Fernanda Villagra
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41650279&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000258(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of TN2011000258A1 publication Critical patent/TN2011000258A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TN2011000258A 2008-11-21 2011-05-20 Pharmaceutical composition of a potent hcv inhibitor for oral administration TN2011000258A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11678908P 2008-11-21 2008-11-21
PCT/US2009/064908 WO2010059667A1 (fr) 2008-11-21 2009-11-18 Composition pharmaceutique d'un inhibiteur puissant du vhc pour une administration orale

Publications (1)

Publication Number Publication Date
TN2011000258A1 true TN2011000258A1 (en) 2012-12-17

Family

ID=41650279

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000258A TN2011000258A1 (en) 2008-11-21 2011-05-20 Pharmaceutical composition of a potent hcv inhibitor for oral administration

Country Status (35)

Country Link
US (2) US20120101049A1 (fr)
EP (1) EP2358355B1 (fr)
JP (1) JP5553839B2 (fr)
KR (1) KR20110087297A (fr)
CN (1) CN102223875A (fr)
AR (1) AR074391A1 (fr)
AU (1) AU2009316755B2 (fr)
BR (1) BRPI0921070A2 (fr)
CA (1) CA2738732A1 (fr)
CL (1) CL2011000878A1 (fr)
CO (1) CO6361900A2 (fr)
CY (1) CY1114892T1 (fr)
DK (1) DK2358355T3 (fr)
EA (1) EA022272B1 (fr)
EC (1) ECSP11011065A (fr)
ES (1) ES2445516T3 (fr)
HR (1) HRP20140097T1 (fr)
IL (1) IL211832A (fr)
MA (1) MA32812B1 (fr)
ME (1) ME01614B (fr)
MX (1) MX2011005151A (fr)
MY (1) MY155402A (fr)
NZ (1) NZ592383A (fr)
PE (1) PE20120032A1 (fr)
PL (1) PL2358355T3 (fr)
PT (1) PT2358355E (fr)
RS (1) RS53121B (fr)
SG (1) SG171771A1 (fr)
SI (1) SI2358355T1 (fr)
TN (1) TN2011000258A1 (fr)
TW (1) TWI469801B (fr)
UA (1) UA105777C2 (fr)
UY (1) UY32252A (fr)
WO (1) WO2010059667A1 (fr)
ZA (1) ZA201102029B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
SG177569A1 (en) 2009-07-07 2012-03-29 Boehringer Ingelheim Int Pharmaceutical composition for a hepatitis c viral protease inhibitor
US20120135949A1 (en) 2010-09-30 2012-05-31 Boehringer Ingelheim International Gmbh Combination therapy for treating hcv infection
EA201390532A1 (ru) * 2010-10-08 2013-09-30 Новартис Аг Композиции сульфамидых ингибиторов ns3, содержащие витамин е
MX2013007677A (es) 2010-12-30 2013-07-30 Abbvie Inc Inhibidores macrociclicos de serina proteasa de hepatitis.
MX2013007698A (es) 2010-12-30 2013-08-15 Abbvie Inc Inhibidores de serina proteasa de hepatitis c macrociclicos de fenantridina.
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
AP2014007760A0 (en) * 2012-01-12 2014-07-31 Boehringer Ingelheim Int Stabilized pharmaceutical formulations of a potentHCV inhibitor
JP2015509980A (ja) 2012-03-14 2015-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法
WO2013147750A1 (fr) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Polythérapie orale pour le traitement d'une infection au vhc dans une sous-population de patients spécifiques
WO2013147749A1 (fr) 2012-03-27 2013-10-03 Boehringer Ingelheim International Gmbh Polythérapie orale pour le traitement d'une infection au vhc dans des populations de sous-génotypes de patients spécifiques
JP2015512900A (ja) 2012-03-28 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法
WO2013169577A1 (fr) * 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Formulation posologique solide orale de [(1s)-1-{[(2s,4r)-4-(7-chloro-4-méthoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-éthénylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-diméthylpropyl]carbamate de 1,1-diméthyléthyle
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
WO2014138374A1 (fr) 2013-03-08 2014-09-12 Boehringer Ingelheim International Gmbh Polythérapie par voie orale pour le traitement d'une infection par le vhc chez une sous-population spécifique de patients
EA029088B1 (ru) 2013-03-15 2018-02-28 Джилид Сайэнс, Инк. Макроциклические и бициклические ингибиторы вируса гепатита c
WO2015103490A1 (fr) 2014-01-03 2015-07-09 Abbvie, Inc. Formes galéniques antivirales solides
WO2017062840A1 (fr) * 2015-10-09 2017-04-13 Trek Therapeutics, Pbc Thérapie combinatoire pour le traitement du virus de l'hépatite c
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
GB0008785D0 (en) * 2000-04-10 2000-05-31 Novartis Ag Organic compounds
CA2466851C (fr) * 2001-11-26 2012-09-11 Supergen, Inc. Procede de preparation et d'utilisation d'huile de ricin polyoxyethylee dans des compositions pharmaceutiques
CZ294371B6 (cs) * 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
PE20050204A1 (es) * 2003-05-21 2005-05-04 Boehringer Ingelheim Int Compuestos inhibidores de la hepatitis c
CA2568008C (fr) * 2004-05-25 2014-01-28 Boehringer Ingelheim International Gmbh Processus de preparation d'inhibiteurs de protease hcv acyclique

Also Published As

Publication number Publication date
PT2358355E (pt) 2014-01-08
TWI469801B (zh) 2015-01-21
CA2738732A1 (fr) 2010-05-27
TW201023859A (en) 2010-07-01
HRP20140097T1 (hr) 2014-03-14
IL211832A0 (en) 2011-06-30
CN102223875A (zh) 2011-10-19
SI2358355T1 (sl) 2014-02-28
JP2012509336A (ja) 2012-04-19
PL2358355T3 (pl) 2014-04-30
ME01614B (me) 2014-09-20
EP2358355A1 (fr) 2011-08-24
AU2009316755A1 (en) 2010-05-27
EP2358355B1 (fr) 2013-11-06
ECSP11011065A (es) 2011-06-30
NZ592383A (en) 2012-11-30
SG171771A1 (en) 2011-07-28
DK2358355T3 (da) 2013-12-16
BRPI0921070A2 (pt) 2019-09-24
UA105777C2 (uk) 2014-06-25
US20120101049A1 (en) 2012-04-26
ES2445516T3 (es) 2014-03-03
ZA201102029B (en) 2011-11-30
CY1114892T1 (el) 2016-12-14
MY155402A (en) 2015-10-15
MA32812B1 (fr) 2011-11-01
AR074391A1 (es) 2011-01-12
UY32252A (es) 2010-06-30
AU2009316755B2 (en) 2015-10-08
EA022272B1 (ru) 2015-12-30
EA201100795A1 (ru) 2012-01-30
IL211832A (en) 2015-02-26
US20150038532A1 (en) 2015-02-05
RS53121B (sr) 2014-06-30
MX2011005151A (es) 2011-05-30
KR20110087297A (ko) 2011-08-02
WO2010059667A1 (fr) 2010-05-27
PE20120032A1 (es) 2012-02-12
CO6361900A2 (es) 2012-01-20
JP5553839B2 (ja) 2014-07-16
CL2011000878A1 (es) 2011-09-02

Similar Documents

Publication Publication Date Title
TN2011000258A1 (en) Pharmaceutical composition of a potent hcv inhibitor for oral administration
WO2010033444A8 (fr) Formes cristallines d'un dérivé 2-thiazolyl-4-quinolinyl-oxy, un inhibiteur puissant du vhc
MX2007004979A (es) Derivados de indol tetraciclicos como agentes antiviricos.
WO2008142055A3 (fr) Agents antiviraux
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
WO2010068760A3 (fr) Nouveaux peptides 4-amino-4-oxobutanoyl utiles en tant qu'inhibiteurs de la réplication virale
WO2007029029A3 (fr) Derives d'indole tetracycliques utilises comme agents antiviraux
MX2011011136A (es) Eteres diarilicos.
MX2009008540A (es) Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.
NZ595280A (en) Hepatitis c virus inhibitors
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
MX2009008541A (es) Fenilcarbamatos macrociclicos que inhiben el virus de hepatitis c.
TW200728307A (en) Novel spirochromanone derivatives
MY154683A (en) Pharmaceutical composition for a hepatitis c viral protease inhibitor
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
TW200806282A (en) Solid dosage formulations
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
WO2006082523A3 (fr) Compositions pharmaceutiques de metformine
UA97369C2 (ru) Противоопухолевые соединения дигидропиран-2-она и фармацевтическая композиция на их основе
TNSN08369A1 (en) Benzimidazole derivatives
TW200626158A (en) Naphthaline derivatives
WO2007146856A3 (fr) Gamma lactames substitués utilisés en tant qu'agents thérapeutiques
PH12013500558A1 (en) Solid state forms of a potent hcv inhibitor
PL2065035T3 (pl) Preparaty farmaceutyczne zawierające irbesartan
TNSN08242A1 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof